Skip to main content
. 2013 Nov 19;36(1):172–181. doi: 10.1007/s11096-013-9876-7

Fig. 1.

Fig. 1

Chronic myeloid leukaemia patients’ utilisation pattern of imatinib and other treatments. *Other treatments include either hematopoietic stem cell transplantation (HSCT) or other tyrosin kinase inhibitors (TKIs). The dot rectangle highlights the multiple switches of imatinib treatment